A microfluidic chip developed at the University of Michigan is among the best at capturing elusive circulating tumor cells from blood—and it can support the cells’ growth for further analysis.
The device, believed to be the first to pair these functions, uses the advanced electronics material graphene oxide. In clinics, such a device could one day help doctors diagnose cancers, give more accurate prognoses and test treatment options on cultured cells without subjecting patients to traditional biopsies.
“If we can get these technologies to work, it will advance new cancer drugs and revolutionize the treatment of cancer patients,” said Max Wicha, M.D., Distinguished Professor of Oncology and director of the U-M Comprehensive Cancer Center and co-author of a paper on the new device, published online this week in Nature Nanotechnology.
“Circulating tumor cells will play a significant role in the early diagnosis of cancer and to help us understand if treatments are working in our cancer patients by serving as a ‘liquid’ biopsy to assess treatment responses in real time,” said co-author Dr. Diane Simeone, the Lazar J. Greenfield Professor of Surgery at the U-M Medical School and director of the Translational Oncology Program.
“Studies of circulating tumor cells will also help us understand the basic biologic mechanisms by which cancer cells metastasize or spread to distant organs—the major cause of death in cancer patients.”
Yet these cells aren’t living up to their promise in medicine because they are so difficult to separate from a blood sample, the researchers say. In the blood of early-stage cancer patients, they account for less than one in every billion cells, so catching them is tougher than finding the proverbial needle in a haystack.
“I can burn the haystack or use a huge magnet,” said Sunitha Nagrath, an assistant professor of chemical engineering, who led the research. “When it comes to circulating tumor cells, they almost look like—feel like—any other blood cell.”
On their microfluidic chip, Nagrath’s team grew dense forests of molecular chains, each equipped with an antibody to grab onto cancer cells.
Even after the cells are caught, it’s still hard to run a robust analysis on just a handful of them, the researchers say. That’s why this demonstration of highly sensitive tumor cell capture, combined with the ability to grow the cells in the same device, is so promising.
Hyeun Joong Yoon, a postdoctoral researcher in the Nagrath lab with a background in electrical engineering, was instrumental in making the microfluidic chip. He started with a silicon base and added a grid of nearly 60,000 flat gold shapes, like four-petaled flowers, each no wider than a strand of hair.
The gold flowers naturally attracted a relatively new material called graphene oxide. These sheets of carbon and oxygen, just a few atoms thick, layered themselves over the gold. This layered formation allowed the team to grow the tumor-cell-catching molecular chains so densely.
“It’s almost like each graphene has many nano-arms to capture cells,” Nagrath said.
To test the device, the team ran one-milliliter samples of blood through the chip’s thin chamber. Even when they had added just three-to-five cancer cells to the 5-10 billion blood cells, the chip was able to capture all of the cells in the sample half the time, with an average of 73 percent over 10 trials.
“That’s the highest anybody has shown in the literature for spiking such a low number of cells,” Nagrath said.
The Latest on: Liquid biopsy
- Startup to commercialize blood test for most major cancers on May 23, 2019 at 5:32 am
The one liquid biopsy product that is currently approved by the Food and Drug Administration is limited in scope, as it tests for an epidermal growth factor receptor mutation that helps doctors ... […]
- Liquid Biopsy with Emphasis on NIPT Marks Dawn of a New Era on May 22, 2019 at 11:31 pm
Tissue biopsies have proved their mettle in medical practices as a means of diagnosing cancer and other diseases. Liquid biopsy has freshly forayed into clinical practice as a robust and relatively ... […]
- Experimental noninvasive tool monitors effectiveness of stem cell transplantation on May 22, 2019 at 4:52 pm
Analysis of the blood test showed responding cells had changed their gene expression, behavior and secretions, suggesting this liquid biopsy could provide a window into stem cell activity and ... […]
- Liquid Biopsy Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2019-2026 on May 22, 2019 at 6:28 am
WiseGuyReports.com adds “Liquid Biopsy Market (by Circulating Biomarker, Product, Application, End User, Clinical Application, Cancer Types, Sample Type, Regional & Country Wise Analysis), Initiatives ... […]
- Biocept's stock soars on heavy volume after commercial launch of liquid biopsy test for lung cancer on May 20, 2019 at 12:07 pm
Shares of Biocept Inc. BIOC, +85.38% soared 86% on very heavy volume Monday, after the provider of liquid biopsy tests announced the commercial launch of Target Selector NGS Lung Panel, the liquid ... […]
- Biocept Announces Clinical Validation and Commercial Launch of its Target Selector™ Multi-Gene Liquid Biopsy Panel for Lung Cancer on May 20, 2019 at 8:15 am
Biocept now positioned as the only commercial liquid biopsy provider that offers single-biomarker testing, tumor-specific panels, and circulating tumor cell analysis SAN DIEGO, May 20, 2019 ... […]
- Liquid Biopsy Helps Identify Cancer Patients at Risk of Metastatic Disease on May 16, 2019 at 7:35 pm
In patients with locally advanced rectal cancer, ctDNA a form of liquid biopsy was found to be more accurate technique to monitor treatment response, said The Royal Marsden NHS Foundation Trust ... […]
- Qiagen teams up with Inovio to develop liquid biopsy companion diagnostic on May 16, 2019 at 2:16 pm
QIAGEN N.V. (NYSE:QGEN) will collaborate with Inovio Pharmaceuticals (NASDAQ:INO) to develop a liquid biopsy-based companion diagnostic test aimed at screening patients who would benefit from the ... […]
- New Study Demonstrates Clinical Utility of Liquid Biopsy for Cancer Monitoring on May 15, 2019 at 5:13 am
Researchers from the University Hospital Basel, the University of Porto and the Hospital of Sao Joao looked at matched tissue and liquid biopsies from 159 NSCLC patients. Among 94 of the patients who ... […]
- Grail Sets Fast Pace in Liquid Biopsy with New Milestones on May 13, 2019 at 7:58 am
The Menlo Park, CA-based company has been granted Break Through Device Designation by FDA, in addition, the company will share new data from the Circulating Cell-free Genome Atlas, at ASCO. ... […]
via Google News and Bing News